Biogen (BIIB) Expert Call Highlights Difficulties with Aduhelm Launch, Numbers Need to Come Down - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $400.00 price target on Biogen (NASDAQ: BIIB) after hosting a KOL ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
